{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:56:12Z","timestamp":1790571372079,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as highly effective therapies for obesity, facilitating weight loss and improving cardiometabolic risk factors. However, several challenges persist regarding optimal long-term management in real-world clinical practice. A board of clinicians with expertise in obesity and metabolic diseases discussed practical recommendations for the sustainable long-term management of GLP-1RA therapy. Key themes included the maintenance of clinical benefits, prevention of weight regain, treatment sustainability, and long-term safety and tolerability. The panel highlighted the necessity of approaching obesity as a chronic, relapsing disease requiring long-term therapeutic strategies. Comprehensive baseline phenotyping and a treat-to-benefit approach were identified as essential for defining clinically meaningful treatment targets beyond weight loss alone. Maintenance therapy after achievement of initial outcomes, flexible dose management, and early recognition of relapse signals were considered essential for preserving benefits and preventing weight regain. Pharmacotherapy should be integrated within a multimodal care model that includes nutritional counseling, physical activity, and behavioral support, while addressing real-world barriers such as economic sustainability. Proactive management of adverse events and patient education were recognized as critical for ensuring long-term adherence. Sustainable use of GLP-1RA therapy requires integrated, patient-centered management strategies that combine pharmacological treatment with lifestyle interventions and pragmatic dose adjustment. Future collaborative real-world data initiatives may further refine these practical recommendations and help optimize long-term obesity care.<\/jats:p>","DOI":"10.3389\/fendo.2026.1907270","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:28:51Z","timestamp":1790569731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice"],"prefix":"10.3389","volume":"17","author":[{"given":"Davide","family":"Brancato","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Casa di Cura Candela","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Borretta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Santa Croce & Carle Hospital","place":["Cuneo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Chianelli","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Metabolism, Regina Apostolorum Hospital","place":["Albano, Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Disoteo","sequence":"additional","affiliation":[{"name":"SC Diabetologia, ASST Grande Ospedale Metropolitano Niguarda","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Grasso","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa (UOC) Malattie Endocrine, del Ricambio e della Nutrizione, AULSS 2 Marca Trevigiana","place":["Treviso, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Diseases of Metabolism and Clinical Nutrition Unit, University Hospital S.M. Misericordia","place":["Udine, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Guastamacchia","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, Interdisciplinary Department of Medicine, University of Bari \u201cAldo Moro\u201d","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Muratori","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetology and Clinical Nutrition, Sant\u2019Anna Hospital - ASST Lariana","place":["Como, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Oleandri","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Unit, Azienda Sanitaria Locale (ASL) CITTA\u2018 di Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Orio","sequence":"additional","affiliation":[{"name":"Medical and Diabetological Center Centro Medico Specialistico Orio (CMSO)","place":["Salerno, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pantanetti","sequence":"additional","affiliation":[{"name":"Azienda Sanitaria Territoriale (AST) Fermo, Unit of Diabetology","place":["Fermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Papini","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Regina Apostolorum Hospital.","place":["Roma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Persichetti","sequence":"additional","affiliation":[{"name":"Ministry of Interior - Department of Firefighters, Public Rescue and Civil Defense","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vettor","sequence":"additional","affiliation":[{"name":"Internal Medicine, Center for the Study and the Integrated Treatment of Obesity, Department of Medicine, University of Padova","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vinciguerra","sequence":"additional","affiliation":[{"name":"Endocrinology Section, Department of Clinical and Experimental Medicine, University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00326-2","article-title":"Obesity legally recognised as a chronic disease in Italy","volume":"13","author":"Bifulco","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(17)30074-9","article-title":"Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120\u2008813 adults from 16 cohort studies from the USA and Europe","volume":"2","author":"Kivim\u00e4ki","year":"2017","journal-title":"Lancet Public Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100805","article-title":"The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity","volume":"6","author":"Scragg","year":"2025","journal-title":"Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2025.103213","article-title":"GLP1-RAs: long-term use versus discontinuation events of an emerging therapy for obesity and cardiovascular diseases","volume":"51","author":"Salerno","year":"2026","journal-title":"Curr Probl Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100162","article-title":"Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials","volume":"13","author":"Guo","year":"2025","journal-title":"Obes Pillars"},{"key":"B10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103796","DOI":"10.1016\/j.eclinm.2026.103796","article-title":"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","volume":"93","author":"Budini","year":"2026","journal-title":"eClinicalMedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70322","article-title":"GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations","volume":"28","author":"Dhippayom","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obes Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1001\/jamainternmed.2024.3579","article-title":"GLP-1 receptor agonists and the path to sustainable obesity care","volume":"185","author":"Manne-Goehler","year":"2025","journal-title":"JAMA Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.2","article-title":"A proposed clinical staging system for obesity","volume":"33","author":"Sharma","year":"2009","journal-title":"Int J Obes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102264","article-title":"Impedance analysis to evaluate nutritional status in physiological and pathological conditions","volume":"15","author":"Catapano","year":"2023","journal-title":"Nutrients"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16263","article-title":"An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes","volume":"27","author":"Bl\u00fcher","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"B22","unstructured":"ICD-11 for Mortality and Morbidity Statistics: 5B81 Obesity\n          \n          \n          \n          2024"},{"key":"B23","unstructured":"WHO Guideline on the Use of Glucagon-Like Peptide-1 (GLP-1) Therapies for the Treatment of Obesity in Adults\n          \n          \n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2025.07.009","article-title":"Cardiometabolic effects of GLP-1 analogs in obese and overweight patients with preexisting cardiovascular disease: A systematic review and meta analysis of randomized controlled trials","volume":"74","author":"Natali","year":"2025","journal-title":"Heart Lung"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70137","article-title":"Reduced-frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series","volume":"34","author":"Wong","year":"2026","journal-title":"Obesity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70538","article-title":"Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX - SEMA 2.4 mg, an Italian real-world study","volume":"28","author":"Pampanelli","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B29","unstructured":"Wegovy - Prescribing Information"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/doci25-0008","article-title":"Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity","volume":"1","author":"Gudzune","year":"2026","journal-title":"BMJ Open Diabetes Res Care Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2025.100228","article-title":"Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach","volume":"17","author":"Sievenpiper","year":"2026","journal-title":"Obes Pillars"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1720794","article-title":"GLP-1 agonists and exercise: the future of lifestyle prioritization","volume":"6","author":"Codella","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103464","article-title":"Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis","volume":"88","author":"Chu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/jobe\/9919810","article-title":"Harnessing GLP-1 receptor agonists for obesity treatment: Prospects and obstacles on the horizon","volume":"2025","author":"Abdelrahman","year":"2025","journal-title":"J Obes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16229","article-title":"Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy","volume":"27","author":"Cengiz","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamainternmed.2025.3599","article-title":"Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: The OASIS 2 randomized clinical trial","volume":"185","author":"Kadowaki","year":"2025","journal-title":"JAMA Intern Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004871","article-title":"Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety","volume":"23","author":"Chao","year":"2026","journal-title":"PloS Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70176","article-title":"Evaluating the evolving real-world adverse events of GLP-1RAs using FDA Adverse Event Reporting System (FAERS)","volume":"34","author":"Stone","year":"2026","journal-title":"Obes (Silver Spring)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"JCM"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1788698","article-title":"Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies","volume":"17","author":"Alhazmi","year":"2026","journal-title":"Front Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S584175","article-title":"Gastrointestinal adverse effects of GLP-1 and dual GLP-1\/GIP receptor agonists: a comprehensive update in diabetic and obese populations","volume":"19","author":"Y\u0131lmaz","year":"2026","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen","volume":"48","author":"Eldor","year":"2025","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X251388724","article-title":"Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1\/GIP receptor agonists: a case series","volume":"13","author":"Tinsley","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70070","article-title":"Micronutrient and nutritional deficiencies associated with GLP \u20101 receptor agonist therapy: A narrative review","volume":"16","author":"Urbina","year":"2026","journal-title":"Clin Obes"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24336","article-title":"Nutritional priorities to support GLP \u20101 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"33","author":"Mozaffarian","year":"2025","journal-title":"Obesity"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1907270\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:28:52Z","timestamp":1790569732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1907270\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":54,"alternative-id":["10.3389\/fendo.2026.1907270"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1907270","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1907270"}}